New study explores UBA1 dysfunction in VEXAS and cancer

A new research perspective was published in Oncotarget’s Volume 15 on September 30, 2024, entitled, “UBA1 dysfunction in VEXAS and cancer.”

Merck is a new year outlier with its diabetes drug

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy New Year, biotech

January 3, 2025

Turning brain immune cells into neurons restores brain function after stroke-like injury in mice

Researchers at Kyushu University have discovered that turning brain immune cells into neurons successfully restores brain function after stroke-like injury in mice.

October 19, 2023

FDA approves first oral treatment for postpartum depression – Pharmaceutical Technology

The most common side effects associated with Zurzuvae are somnolence or sleepiness, dizziness, diarrhoea, fatigue, and urinary tract infection. Image Credit: Nicoleta Ionescu / Shutterstock.

August 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.